Lurbinectedin is a drug used to treat cancer, and it has been shown to be effective in treating certain types of cancer. However, it is not effective for all types of cancer. According to the sources provided, Lurbinectedin has been approved for the treatment of small cell lung cancer (SCLC) [1]. A clinical trial has also been conducted to test the effectiveness of Lurbinectedin in treating advanced solid tumors, including ovarian, endometrial, and breast cancer. The results of the trial showed that Lurbinectedin had some effectiveness in treating these types of cancer [3]. However, it is important to note that the effectiveness of Lurbinectedin may vary depending on the type of cancer being treated.

In addition, the cost-effectiveness of Lurbinectedin as a second-line treatment for SCLC has been studied [2]. The study found that Lurbinectedin was cost-effective when compared to other treatment options for SCLC.

Overall, Lurbinectedin has shown promise in treating certain types of cancer, particularly SCLC. However, more research is needed to determine its effectiveness in treating other types of cancer.

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.targetedonc.com/view/lurbinectedin-is-cost-effective-as-a-second-line-treatment-in-sclc
[3] https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/c82382